Artiva Biotherapeutics Halts AlloNK Cell Therapy Trials
The company is ending development of its autoimmune cell therapy following two patient deaths in clinical trials.
Updated on Oct. 27, 2026 in Biotech
Artiva Biotherapeutics has officially halted development of its experimental AlloNK cell therapy following the deaths of two patients in a clinical trial. The company is concurrently reducing its workforce by 94 percent while evaluating strategic alternatives.
Why it matters
This clinical failure marks a significant setback for the company, as the two patient deaths during autoimmune condition testing forced the immediate discontinuation of its primary therapeutic candidate.
The company held $319.1 million in cash, cash equivalents, and investments as of September 30, 2026. This liquidity follows a period where the firm employed 104 full-time staff as of December 31, 2025.
The players
Artiva Biotherapeutics
A biotech firm focused on developing off-the-shelf natural killer cell therapies for autoimmune diseases and oncology.
The details
AlloNK was an experimental cell therapy designed to treat autoimmune conditions through a mid-stage clinical trial. Investigators attributed one fatal neurological event to complications from fludarabine, a chemotherapy drug often used in conditioning regimens before cell therapy, while the second patient death was classified as unrelated to the treatment.
Timeline
December 31, 2025: The company employed 104 full-time staff.
September 30, 2026: Artiva Biotherapeutics held $319.1 million in liquid assets.
October 27, 2026: The company announced the therapy discontinuation and workforce reduction.
The Tech Race
This discontinuation disrupts the broader race to develop effective allogeneic natural killer cell therapies for autoimmune conditions. Artiva Biotherapeutics now follows a trend of narrowing pipelines as smaller firms pivot following negative clinical data.
Patients previously enrolled in or screening for AlloNK trials must coordinate with their clinical site investigators for ongoing medical management. Future access to the experimental treatment is effectively nullified as the company terminates the program.
The takeaway
The termination of this program underscores the volatile path of cell therapy development in autoimmune treatment. Stakeholders should monitor the company's SEC filings for updates regarding the sale of assets or remaining capital distribution.
Further reading
For broader trends in the industry, see our analysis of Biotech.
